-
Signature
-
Donna Kalazdy, by power of attorney from Michael David Garrison
-
Issuer symbol
-
BDX
-
Transactions as of
-
15 Jan 2026
-
Net transactions value
-
-$334,094
-
Form type
-
4
-
Filing time
-
16 Jan 2026, 15:43:46 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Garrison Michael David |
EVP & Pres Med.Essntl&BioPharm |
C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES |
Donna Kalazdy, by power of attorney from Michael David Garrison |
16 Jan 2026 |
0001944816 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
BDX |
Common Stock |
Options Exercise |
$512,797 |
+3,054 |
+23% |
$167.91 |
16,159 |
15 Jan 2026 |
Direct |
|
| transaction |
BDX |
Common Stock |
Disposed to Issuer |
$512,886 |
-2,454 |
-15% |
$209.00 |
13,705 |
15 Jan 2026 |
Direct |
|
| transaction |
BDX |
Common Stock |
Sale |
$125,400 |
-600 |
-4.4% |
$209.00 |
13,105 |
15 Jan 2026 |
Direct |
|
| transaction |
BDX |
Common Stock |
Sale |
$208,605 |
-1,010 |
-7.7% |
$206.54 |
12,095 |
15 Jan 2026 |
Direct |
|
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
BDX |
Stock Appreciation Rights |
Options Exercise |
$0 |
-3,054 |
-100% |
$0.000000 |
0 |
15 Jan 2026 |
Common Stock |
3,054 |
$167.91 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses:
Remarks:
The reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 13, 2025.